EAM Investors’s Seres Therapeutics MCRB Stock Holding History

EAM Investors’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-6,680	Closed	-$3.78M	–	354
2020 Q3	$3.78M	Buy	+6,680	New	+$2.22M	0.9%	8

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

EAM Investors's MCRB Position: Q4 2020 in Review

EAM Investors sold out of Seres Therapeutics (MCRB) in Q4 2020, closing a stake of 6,680 shares — an estimated $3.78M sold.

EAM Investors first reported a position in MCRB in Q3 2020 and held it in 1 quarter. The position peaked at $3.78M in Q3 2020. 152 funds tracked by Wall St. Rank hold MCRB as of Q4 2020.

EAM Investors reported no remaining Seres Therapeutics position as of Q4 2020 after selling out during the quarter.
EAM Investors sold 6,680 Seres Therapeutics shares in Q4 2020, an estimated $3.78M.
EAM Investors first reported a position in Seres Therapeutics in Q3 2020 and held it in 1 quarter.
EAM Investors's Seres Therapeutics position peaked at $3.78M in Q3 2020.
152 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2020.

Based on EAM Investors's 13F filing for Q4 2020, filed 11 Feb 2021.